Clinical trials: 5-FU, completed
Pancreatic Cancer
Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer
The purpose of this study is to explore whether adjuvant chemotherapy regimens guided by organoid drug sensitivity test can improve the outcomes of pancreatic cancer.
- Trial name
- NCT04931394
- Testing
- Adjuvant chemotherapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Changhai Hospital
Pancreatic Cancer Resectable
Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.
This prospective and open-label study evaluates the efficacy and safety of mFOLFIRINOX as postoperative chemotherapy in treating Chinese patients with pancreatic cancer after R0/R1 resection.
- Trial name
- NCT04224402
- Testing
- mFOLFORINOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Yuhong Li
Esophageal Neoplasms
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
To determine the activity and efficacy of the schema specified as dose regimen To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU
- Trial name
- NCT00259402
- Testing
- Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Sanofi
Head and Neck Cancer
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck
To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU) in patients with advanced inoperable or metastatic head and neck cancer and to investigate the safety profile of this regimen in the…
- Trial name
- NCT00611754
- Testing
- Oxaliplatin, 5-FU
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Sanofi
Colorectal Cancer, Metastasis
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
The standard treatment of metastatic colorectal cancer is based on systemic chemotherapy. Several effective drugs are currently available and can be administered either sequentially or in combination.
- Trial name
- NCT00126256
- Testing
- 5-fluorouracil, leucovorin, irinotecan
- Where
- France
- Volunteers
- 570 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Malignant Tumor, Diarrhea
XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)
Run-in safety study, to determine the safety of co-administration of irinotecan, raloxifene, and Xiao Chai Hu Tang (XCHT), and to optimize the blood collection time points for pharmacokinetic (PK) study for another randomized…
- Trial name
- NCT04926545
- Testing
- Xiao Chai Hu Tang (XCHT), Raloxifene, FOLFIRI regimen
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Head and Neck Cancer
A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck
The primary objective of the study is to evaluate time to progression in eligible patients with cancer of the oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus when treated with the concomitant…
- Trial name
- NCT00203905
- Testing
- 5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab, 5-Fluorouracil, Hydroxyurea-[FHX]
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Chicago
Gastroesophageal Junction Adenocarcinoma
Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing neoadjuvant radiochemotherapy with FLOT versus FLOT chemotherapy alone für patients with locally advanced, potentially resectable…
- Trial name
- NCT04375605
- Testing
- 5-Fluorouracil, Calcium folinate, Oxaliplatin
- Where
- Germany
- Volunteers
- 342 people
- Sponsor
- Universitätsmedizin Mannheim
Hepatocellular Carcinoma
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.
- Trial name
- NCT05864105
- Testing
- PM8002, FOLFOX regimen
- Where
- 9 sites in China
- Volunteers
- 35 people
- Sponsor
- Biotheus Inc.
Colorectal Neoplasm, Secondary Malignant Neoplasm of Liver
Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only
This is a Phase III trial comparing hepatic intra-arterial injection of Yttrium-90 microspheres (selective internal radiation [SIR] spheres) versus infusional intravenous (IV) 5FU in colorectal cancer metastatic to the liver only…
- Trial name
- NCT00199173
- Testing
- SIR Spheres intra-arterial hepatic
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Stomach Cancer, Esophageal Cancer
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.
- Trial name
- NCT01246960
- Testing
- Ramucirumab, Oxaliplatin, Leucovorin
- Where
- 58 sites in United States
- Volunteers
- 168 people
- Sponsor
- Eli Lilly and Company
Metastatic Cancer, Cancer
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as…
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Trial name
- NCT01957735
- Testing
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- BPGbio
Metastatic Colorectal Cancer, KRAS Gene Mutation
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line…
- Trial name
- NCT03829410
- Testing
- Onvansertib, Bevacizumab, FOLFIRI
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Cardiff Oncology
Pancreatic Cancer
The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a poor prognosis, despite the emergence of chemotherapies, unmet medical needs and limited treatment options still exist for patients with metastatic PDAC…
- Trial name
- NCT06378580
- Testing
- Surufatinib combine immune checkpoint inhibitor, AG/FOLFIRINOX
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Luo Cong
Metastatic Colorectal Cancer
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as CMAB009, can block tumor growth in different ways.
- Trial name
- NCT03206151
- Testing
- CMAB009, Irinotecan, Folinic acid
- Where
- 2 sites in China
- Volunteers
- 520 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Metastatic Colorectal Cancer
Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
This is a phase II, randomized, multi-center, open-label, parallel-group study to evaluate the progression-free survival during maintenance therapy. Eligible patients will be treated within a 12-week induction therapy.
- Trial name
- PanaMa (NCT01991873)
- Testing
- Maintenance Chemotherapy, Panitumumab (Within maintenance phase), mFOLFOX6 (Within re-induction phase)
- Where
- 2 sites in Germany
- Volunteers
- 387 people
- Sponsor
- AIO-Studien-gGmbH
Gastric Cancer
A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
This study will evaluate the efficacy and safety of oral capecitabine (Xeloda) versus 5-fluorouracil (5-FU), in combination with intravenous (IV) cisplatin, in participants with advanced and/or metastatic gastric cancer.
- Trial name
- NCT02563054
- Testing
- 5-Fluorouracil, Capecitabine, Cisplatin
- Where
- 45 sites in Argentina, Belize and 12 more
- Volunteers
- 316 people
- Sponsor
- Hoffmann-La Roche
Neuroendocrine Tumors
5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
Well differentiated neuroendocrine carcinomas have low proliferative activity and conventional chemotherapy is not recommended. Metronomic chemotherapy, i.e.
- Trial name
- NCT00953394
- Testing
- continuous 5 fluouracil infusion plus long-acting octreotide
- Where
- 7 sites in Italy
- Volunteers
- 29 people
- Sponsor
- University of Turin, Italy
Breast Cancer
Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer
This is a phase IV, prospective, single-center, open-label, randomized, controlled study. Eligible patients are randomly assigned into three groups.
- Trial name
- NCT01199432
- Testing
- 5-FU（intravenous infusion）+epirubicin+cyclophosphamide, 5-FU（intravenous bolus）+epirubicin+cyclophosphamide, epirubicin+cyclophosphamide
- Where
- China
- Volunteers
- 501 people
- Sponsor
- Tao OUYANG
Gastric Cancer
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003298
- Testing
- cisplatin, fluorouracil, leucovorin calcium
- Where
- 30 sites in United States
- Volunteers
- 39 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.